BACKGROUND: we have observed the effect of insomnia treatment in clinical and prognostic differences of patients admitted for COVID-19 pneumonia in respiratory sub-intensive units that were administered a prolonged-release melatonin 2 mg (PRM 2 mg) therapy versus a group of patients out of therapy. MATERIALS AND METHODS: We evaluated 40 patients on prolonged-release melatonin 2 mg (PRM 2 mg) therapy versus a control group of 40 patients out of therapy. RESULTS: patients in the PRM 2 mg group had a shorter duration of therapy with non-invasive ventilation (5.2 ± 3.0 vs. 12.5 ± 4.2; p < 0.001), with a shorter stay in sub-intensive care (12.3 ± 3.2 vs. 20.1 ± 6.1; p < 0.001), and, therefore, a shorter overall duration of hospitalization (31.3 ± 6.8 vs. 34.3 ± 6.9 p = 0.03). In addition, a lower incidence of delirium was found (2.2 ± 1.1 vs. 3.3 ± 1.3; p < 0.001). CONCLUSIONS: A significant increase in sleep hours and a reduction in delirium episodes occurs in hospitalized insomniac patients treated with PRM 2 mg, compared to untreated patients. Based on these preliminary results, we can assume that there are benefits of prolonged-release melatonin 2 mg in COVID-19 therapy.
BACKGROUND: we have observed the effect of insomnia treatment in clinical and prognostic differences of patients admitted for COVID-19 pneumonia in respiratory sub-intensive units that were administered a prolonged-release melatonin 2 mg (PRM 2 mg) therapy versus a group of patients out of therapy. MATERIALS AND METHODS: We evaluated 40 patients on prolonged-release melatonin 2 mg (PRM 2 mg) therapy versus a control group of 40 patients out of therapy. RESULTS: patients in the PRM 2 mg group had a shorter duration of therapy with non-invasive ventilation (5.2 ± 3.0 vs. 12.5 ± 4.2; p < 0.001), with a shorter stay in sub-intensive care (12.3 ± 3.2 vs. 20.1 ± 6.1; p < 0.001), and, therefore, a shorter overall duration of hospitalization (31.3 ± 6.8 vs. 34.3 ± 6.9 p = 0.03). In addition, a lower incidence of delirium was found (2.2 ± 1.1 vs. 3.3 ± 1.3; p < 0.001). CONCLUSIONS: A significant increase in sleep hours and a reduction in delirium episodes occurs in hospitalized insomniac patients treated with PRM 2 mg, compared to untreated patients. Based on these preliminary results, we can assume that there are benefits of prolonged-release melatonin 2 mg in COVID-19 therapy.
Authors: Laura Palagini; Raffaele Manni; Eugenio Aguglia; Mario Amore; Roberto Brugnoli; Paolo Girardi; Luigi Grassi; Claudio Mencacci; Giuseppe Plazzi; Antonino Minervino; Lino Nobili; Giovanni Biggio Journal: Front Psychiatry Date: 2020-06-26 Impact factor: 4.157
Authors: Alan G Wade; Ian Ford; Gordon Crawford; Alex D McMahon; Tali Nir; Moshe Laudon; Nava Zisapel Journal: Curr Med Res Opin Date: 2007-10 Impact factor: 2.580
Authors: Virna Margarita Martín Giménez; Felipe Inserra; Carlos D Tajer; Javier Mariani; León Ferder; Russel J Reiter; Walter Manucha Journal: Life Sci Date: 2020-05-15 Impact factor: 5.037
Authors: Erica B Baller; Charlotte S Hogan; Mark A Fusunyan; Ana Ivkovic; James W Luccarelli; Elizabeth Madva; Mladen Nisavic; Nathan Praschan; Nadia V Quijije; Scott R Beach; Felicia A Smith Journal: Psychosomatics Date: 2020-05-21 Impact factor: 2.386